■建议将5:2IF饮食(间歇性禁食)和每日热量限制饮食用于治疗MAFLD(代谢相关脂肪肝),这项研究旨在评估5:2IF饮食对MAFLD成人体重和代谢参数的影响,与每日热量限制饮食相比。
■这个单中心,双盲,prospective,随机对照试验包括60例MAFLD患者,每周给予5:2的IF饮食限制卡路里消耗2天,其余5天不受限制(第5组:2的IF饮食)或每日热量限制进食(第2组每日热量限制)。Fibortouch-B仪器评估,肝脏脂肪变性的超声评估,人体测量指数和身体成分分析,在两次不同的访视期间进行血液样本测量:最初在研究开始之日(T1),随后在12周干预期(T2)结束时。
■与每日热量限制饮食相比,5:2IF饮食显着降低肝性脂肪变性≥中度的比例(29.6%vs.59.3%,p=0.028)和肝纤维化程度F≥2(3.7%vs.25.9%,p=0.05),在5:2间歇性禁食饮食组中,通过上腹部超声诊断为脂肪肝的患者比例较少(33.3%vs.63.0%,p=0.029)。此外,5:2IF饮食组的CAP(受控衰减参数)和LSM(肝脏硬度测量)值显着降低(p<0.05)。两组在体重方面无统计学差异,BMI(体重指数),WC(腰围),HC(臀围),和WHR(腰臀比)。同样,血脂谱没有显著差异,血糖指标和不良事件(p>0.05)。
■总之,尽管5:2IF饮食和每日热量限制饮食对体重的影响相似,肝酶,治疗12周后的血脂和血糖指数,图5:2IF饮食显示出独立于体重调节的纤维化和脂肪变性评分的更好改善。因此,在被诊断为MAFLD的患者中,它有望成为生活方式干预的可行饮食方式.
■https://www.crd.约克。AC.英国/PROSPERO,标识符ChiCTR2400080292。
UNASSIGNED: Both 5:2 IF diet (intermittent fasting) and daily caloric restriction eating had been suggested for management of MAFLD (Metabolic-Associated Fatty Liver Disease), this study aimed to evaluate the effects of 5:2 IF diet on body weight and metabolic parameters in adults with MAFLD, in comparison to daily caloric restriction eating.
UNASSIGNED: This single-center, double-blind, prospective, randomized controlled trial included 60 patients with MAFLD, who were administered either a 5:2 IF diet limited calories consumed for 2 days each week with no restrictions on the remaining 5 (Group 5:2 IF diet) or a daily calorie restriction eating (Group daily calorie restriction). Fibrotouch-B instrument assessment, ultrasound assessment of hepatic steatosis, anthropometric indices and body composition analysis, blood sample measurements were conducted during two distinct visits: initially on the day of study commencement (T1), and subsequently at the conclusion of the 12-week intervention period (T2).
UNASSIGNED: In comparison to daily calorie restriction eating, the 5:2 IF diet significantly decreased the proportion of hepatic steatosis ≥moderate (29.6% vs. 59.3%, p = 0.028) and the degree of hepatic fibrosis F ≥ 2 (3.7% vs. 25.9%, p = 0.05), and fewer percentage of patients were diagnosed with fatty liver via upper abdominal ultrasound in the 5:2 intermittent fasting diet group (33.3% vs. 63.0%, p = 0.029). Additionally, the CAP (controlled attenuation parameter) and LSM (liver stiffness measurements) value were significantly lower in the 5:2 IF diet group (p < 0.05). No statistically significant differences were observed between the two groups in terms of weight, BMI (body mass index), WC (waist circumference), HC (hip circumference), and WHR (waist to hip ratio). Similarly, there were no significant differences in lipid profile, glycemic indices and adverse events (p > 0.05).
UNASSIGNED: In summary, although both 5:2 IF diet and daily caloric restriction eating achieved similar effect on body weight, liver enzymes, lipid profile and glycemic indices after 12 weeks treatment, 5:2 IF diet demonstrates better improvement in fibrosis and steatosis scores independently from weight regulation. Consequently, it is anticipated to emerge as a viable dietary modality for lifestyle intervention among patients diagnosed with MAFLD.
UNASSIGNED: https://www.crd.york.ac.uk/PROSPERO, identifier ChiCTR2400080292.